OnabotulinumtoxinA as a promising treatment for primary trochlear headache: A retrospective case series.

Autor: Jaimes A; Headache Unit, Department of Neurology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.; School of Medicine, Autonomous University of Madrid, Madrid, Spain., Gómez A; Headache Unit, Department of Neurology, Fundación Jiménez Díaz University Hospital, Madrid, Spain., Pajares O; Headache Unit, Department of Neurology, Fundación Jiménez Díaz University Hospital, Madrid, Spain., Rodríguez-Vico J; Headache Unit, Department of Neurology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Jazyk: angličtina
Zdroj: Headache [Headache] 2024 May; Vol. 64 (5), pp. 589-594. Date of Electronic Publication: 2024 Mar 27.
DOI: 10.1111/head.14699
Abstrakt: Objectives: To report the efficacy of onabotulinumtoxinA (BoNTA) injections in relieving pain in patients with primary trochlear headache (PRTH).
Methods: Examination of medical records for patients diagnosed with PRTH according to the International Classification of Headache Disorders, 3rd edition criteria and treated with BoNTA. Data were collected for variables related to pain relief, duration of effectiveness, and adverse effects.
Results: Six patients were included in the study. All had previously undergone standard care interventions, including infiltrations or oral treatments, yet experienced treatment failure or symptom recurrence. All patients received 20 units of BoNTA, administered in the corrugator and procerus muscles. Subsequent to the BoNTA injections, all six patients reported substantial pain relief, with five achieving complete remission of symptoms. The analgesic effect persisted for a duration of 3 months. No adverse events were reported in any of the cases.
Conclusions: Our case series presents the first evidence of the potential of BoNTA as a safe and effective treatment option for PRTH. From a clinical standpoint, having a safer alternative is of paramount significance for patients with limited treatment options, such as those with PRTH. Further research is warranted to validate these findings and explore the long-term efficacy of BoNTA in PRTH management.
(© 2024 The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society.)
Databáze: MEDLINE
Externí odkaz: